• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

小干扰RNA与RNA干扰优化

siRNA and RNAi optimization.

作者信息

Alagia Adele, Eritja Ramon

机构信息

Chemical and Biomolecular Nanotechnology, CIBER-BBN, Institute for Advanced Chemistry of Catalonia, IQAC-CSIC, Barcelona, Spain.

出版信息

Wiley Interdiscip Rev RNA. 2016 May;7(3):316-29. doi: 10.1002/wrna.1337. Epub 2016 Feb 2.

DOI:10.1002/wrna.1337
PMID:26840434
Abstract

The discovery and examination of the posttranscriptional gene regulatory mechanism known as RNA interference (RNAi) contributed to the identification of small interfering RNA (siRNA) and the comprehension of its enormous potential for clinical purposes. Theoretically, the ability of specific target gene downregulation makes the RNAi pathway an appealing solution for several diseases. Despite numerous hurdles resulting from the inherent properties of siRNA molecule and proper delivery to the target tissue, more than 50 RNA-based drugs are currently under clinical testing. In this work, we analyze the recent literature in the optimization of siRNA molecules. In detail, we focused on describing the most recent advances of siRNA field aimed at optimize siRNA pharmacokinetic properties. Special attention has been given in describing the impact of RNA modifications in the potential off-target effects (OTEs) such as saturation of the RNAi machinery, passenger strand-mediated silencing, immunostimulation, and miRNA-like OTEs as well as to recent developments on the delivery issue. The novel delivery systems and modified siRNA provide significant steps toward the development of reliable siRNA molecules for therapeutic use. WIREs RNA 2016, 7:316-329. doi: 10.1002/wrna.1337 For further resources related to this article, please visit the WIREs website.

摘要

对被称为RNA干扰(RNAi)的转录后基因调控机制的发现与研究,推动了小干扰RNA(siRNA)的鉴定,并有助于理解其在临床应用中的巨大潜力。从理论上讲,特异性下调靶基因的能力使RNAi途径成为治疗多种疾病的一个有吸引力的解决方案。尽管siRNA分子的固有特性以及将其有效递送至靶组织存在诸多障碍,但目前仍有50多种基于RNA的药物正在进行临床试验。在这项工作中,我们分析了近期关于优化siRNA分子的文献。具体而言,我们着重描述了siRNA领域为优化其药代动力学特性所取得的最新进展。在描述RNA修饰对潜在脱靶效应(OTE)的影响时给予了特别关注,这些效应包括RNAi机制的饱和、过客链介导的沉默、免疫刺激以及miRNA样OTE,同时也关注了递送问题的最新进展。新型递送系统和修饰后的siRNA为开发可靠的治疗用siRNA分子迈出了重要步伐。《WIREs RNA》2016年,7卷:316 - 329页。doi: 10.1002/wrna.1337 如需获取与本文相关的更多资源,请访问WIREs网站。

相似文献

1
siRNA and RNAi optimization.小干扰RNA与RNA干扰优化
Wiley Interdiscip Rev RNA. 2016 May;7(3):316-29. doi: 10.1002/wrna.1337. Epub 2016 Feb 2.
2
Hydrophobization and bioconjugation for enhanced siRNA delivery and targeting.用于增强siRNA递送和靶向的疏水化与生物共轭作用。
RNA. 2007 Apr;13(4):431-56. doi: 10.1261/rna.459807. Epub 2007 Feb 28.
3
Chemical and structural modifications of RNAi therapeutics.RNAi 治疗药物的化学和结构修饰。
Adv Drug Deliv Rev. 2016 Sep 1;104:16-28. doi: 10.1016/j.addr.2015.10.015. Epub 2015 Nov 5.
4
Toxicogenomics of non-viral drug delivery systems for RNAi: potential impact on siRNA-mediated gene silencing activity and specificity.用于RNA干扰的非病毒药物递送系统的毒理基因组学:对小干扰RNA介导的基因沉默活性和特异性的潜在影响。
Adv Drug Deliv Rev. 2007 Mar 30;59(2-3):164-82. doi: 10.1016/j.addr.2007.03.010. Epub 2007 Mar 21.
5
Small-interfering RNA (siRNA)-based functional micro- and nanostructures for efficient and selective gene silencing.基于小干扰 RNA (siRNA) 的功能微纳结构用于高效和选择性基因沉默。
Acc Chem Res. 2012 Jul 17;45(7):1014-25. doi: 10.1021/ar2002254. Epub 2012 Mar 13.
6
Modification of the siRNA passenger strand by 5-nitroindole dramatically reduces its off-target effects.通过 5-硝基吲哚对 siRNA 过客链进行修饰可显著降低其脱靶效应。
Chembiochem. 2012 Sep 3;13(13):1940-5. doi: 10.1002/cbic.201200349. Epub 2012 Aug 7.
7
Harnessing RNA interference to develop neonatal therapies: from Nobel Prize winning discovery to proof of concept clinical trials.利用 RNA 干扰开发新生儿疗法:从诺贝尔奖获奖发现到概念验证临床试验。
Early Hum Dev. 2009 Oct;85(10 Suppl):S31-5. doi: 10.1016/j.earlhumdev.2009.08.013. Epub 2009 Oct 14.
8
Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges.用于癌症治疗中 siRNA 递送的基于脂质的纳米颗粒:范例与挑战。
Acc Chem Res. 2012 Jul 17;45(7):1163-71. doi: 10.1021/ar300048p. Epub 2012 May 8.
9
Overview of gene silencing by RNA interference.RNA干扰介导的基因沉默概述。
Curr Protoc Nucleic Acid Chem. 2009 Mar;Chapter 16:Unit 16.1. doi: 10.1002/0471142700.nc1601s36.
10
Tolerance of RNA interference toward modifications of the 5' antisense phosphate of small interfering RNA.RNA干扰对小干扰RNA 5'反义磷酸修饰的耐受性。
Oligonucleotides. 2007 Spring;17(1):35-43. doi: 10.1089/oli.2006.0067.

引用本文的文献

1
Chemical Strategies to Enhance Antisense Strand Selection and Minimize Off-Target Effect-Mediated by siRNAs.增强反义链选择并最小化由小干扰RNA介导的脱靶效应的化学策略。
Methods Mol Biol. 2025;2965:479-488. doi: 10.1007/978-1-0716-4742-4_25.
2
Small Interfering RNA (siRNA) for Cardiorenal Disease: Mechanistic Insights from Preclinical and Clinical Studies.用于心肾疾病的小干扰RNA(siRNA):来自临床前和临床研究的机制见解
J Cardiovasc Transl Res. 2025 Jun 25. doi: 10.1007/s12265-025-10649-4.
3
Dioscin alleviates the dysfunction of fibroblast-like synoviocytes by circ_0008267/miR-942-5p/FKBP5 axis during rheumatoid arthritis.
薯蓣皂苷在类风湿性关节炎期间通过circ_0008267/miR-942-5p/FKBP5轴减轻成纤维样滑膜细胞功能障碍。
Naunyn Schmiedebergs Arch Pharmacol. 2025 Mar 21. doi: 10.1007/s00210-025-03872-y.
4
LncRNA MKLN1-AS promotes glioma tumorigenesis and growth via activating the Hippo pathway through miR-126-5p/TEAD1 axis.长链非编码RNA MKLN1-AS通过miR-126-5p/TEAD1轴激活Hippo信号通路,促进神经胶质瘤的发生和生长。
Naunyn Schmiedebergs Arch Pharmacol. 2024 Dec 16. doi: 10.1007/s00210-024-03646-y.
5
CircAKR1B10 interacts with EIF4A3 to stabilize AURKA and promotes IL-22-induced proliferation, migration and invasion in keratinocytes.环状 AKR1B10 与 EIF4A3 相互作用稳定 AURKA,促进角质形成细胞中 IL-22 诱导的增殖、迁移和侵袭。
Arch Dermatol Res. 2024 Aug 23;316(8):561. doi: 10.1007/s00403-024-03302-8.
6
STAT3-specific nanocarrier for shRNA/drug dual delivery and tumor synergistic therapy.用于shRNA/药物双重递送和肿瘤协同治疗的STAT3特异性纳米载体。
Bioact Mater. 2024 Jul 17;41:137-157. doi: 10.1016/j.bioactmat.2024.07.010. eCollection 2024 Nov.
7
METTL3 facilitates prostate cancer progression via inducing HOXC6 m6A modification and stabilizing its expression through IGF2BP2-dependent mechanisms.METTL3 通过诱导 HOXC6 m6A 修饰并通过 IGF2BP2 依赖性机制稳定其表达促进前列腺癌进展。
Mol Cell Biochem. 2024 Jul;479(7):1707-1720. doi: 10.1007/s11010-024-05023-y. Epub 2024 May 31.
8
LDLR-Mediated Targeting and Productive Uptake of siRNA-Peptide Ligand Conjugates In Vitro and In Vivo.低密度脂蛋白受体介导的小干扰RNA-肽配体缀合物在体外和体内的靶向及有效摄取
Pharmaceutics. 2024 Apr 17;16(4):548. doi: 10.3390/pharmaceutics16040548.
9
The Circular RNA Circ_0043947 Promoted Gastric Cancer Progression by Sponging miR-384 to Regulate CREB1 Expression.环状 RNA Circ_0043947 通过海绵吸附 miR-384 调控 CREB1 表达促进胃癌进展。
Gut Liver. 2024 Nov 15;18(6):977-991. doi: 10.5009/gnl230173. Epub 2024 Apr 19.
10
RNA-based Therapeutics: Past, Present and Future Prospects, Challenges in Cancer Treatment.基于 RNA 的治疗方法:癌症治疗的过去、现在和未来前景、挑战。
Curr Pharm Biotechnol. 2024;25(16):2125-2137. doi: 10.2174/0113892010291042240130171709.